

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		1136/1/US (Pfizer Ref. 27520/USA)	10/603,441
Sheet 1 of 2		APPLICANTS	
		Daniel P. Becker, et al.	
		FILING DATE	GROUP
		June 25, 2003	1625

#### U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	CC	6,683,078	1/27/04	Barta et al.	514/231.5	7/12/02
2.		6,683,093	1/27/04	Barta, et al.	514/316	11/21/01
3.		6,689,794	2/10/04	Freskos, et al.	514/318	5/10/02
4. (office actions, advisory action, and notice of allowance enclosed)		6,750,228, including 5/31/01 Office action, 10/5/01 Office action, 4/11/03 Office action, 9/11/03 advisory action, and 9/30/03 notice of allowance	6/15/04	Barta et al.	514/316	5/12/00
5.		6,750,233	6/15/04	Barta et al.	514/336	9/17/01
6. (enclosed)		11/20/03 Office action and 7/28/04 Office action from Abandoned Appl. No. 09/311,837		Barta, et al.		5/14/1999
7. (allowed claims and notice of allowance enclosed)		Appl. Publ. No. 2004-0048852 (Appl. No. 10/337,942), including allowed claims and 2/13/04 notice of allowance		Barta, et al.	514/317	1/7/03
8. (pending claims enclosed)	CC	Appl. Publ. No. 2004-0235818 (Appl. No. 10/747,796), including pending claims		Barta et al.	514/315	12/29/03

#### FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	Translation No
9. (enclosed)	a	EP 0 994 104	4/19/00	Europe	C07C 317/44	<input checked="" type="checkbox"/>	<input type="checkbox"/>
10. (enclosed)	u	WO 03/045944	6/5/03	PCT	C07D 405/12	<input type="checkbox"/>	<input checked="" type="checkbox"/>

Examiner:

*Chay*

Date Considered:

*5/4/05*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*327050075 US*

<p><b>FORM HDP-1449 (Based on Form PTO-1449)</b></p> <p><b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE CITATION</b>  (Use several sheets if necessary)</p> <p>Sheet 2 of 2</p>	<b>ATTORNEY DOCKET NO.</b>	<b>SERIAL NO.</b>
	01136/1/US (Pfizer Ref. 27520/USA)	10/603,441
	<b>APPLICANT</b>	
	Daniel P. Becker, et al.	
	<b>FILING DATE</b>	<b>GROUP</b>
June 25, 2003	1625	

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
11. (enclosed)	<i>cl</i>	Search Report and Preliminary Examination Report for International Application No. PCT/US03/20028

Examiner:	<i>Chay</i>	Date Considered:	<i>5/4/05</i>
-----------	-------------	------------------	---------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 1 of 1

ATTORNEY DOCKET NO.	SERIAL NO.
01136/1/US	10/603,441
APPLICANTS	
Daniel P. Becker, et al.	
FILING DATE	GROUP
June 25, 2003	1614 16 25

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	Translation No
1.	CL	WO 00/18741	4/6/00	PCT	C07D/ 231/00		

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)**

Ref. Desig.	Examiner's Initials	
2.	CL	Janczewski, Marian et al., "Effect of Molecular Structure on Optical Properties of Sulfoxide Systems. Parts LV and LVI. Optical Relationships in the 4-Diphenylsulfinylacetic Acids Group and Their 4'-Ethyl and 4'-t-Butyl Derivatives", Roczniki Chemii, vol. 48, pages 409-431 (1974)
3.	CL	Gajadhar, Alvin et al., "Phenylsulfonylacetamide Derivatives as New Compounds with Potential Biological Activity", Pestycydy, vol. 3-4, pages 5-9 (2001)


Examiner:

CL

Date Considered:

5/4/03

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
SEP 29 2003  
TELEFAX CENTER 16022000

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET NO.	SERIAL NO.
01136/1/US	10/603,441
APPLICANTS	
Daniel P. Becker, et al.	
FILING DATE	GROUP
June 25, 2003	1614

**U.S. PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

**FOREIGN PATENT DOCUMENTS**

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	Translation No
32.	cl	WO 99/42436	8/26/99	PCT	C07C 239/14	-	
33.	1	WO 99/25687	5/27/99	PCT	C07D 211/66		
34.		WO 99/09000	2/25/99	PCT	C07C 235/00		
35.		WO 98/38163	9/3/98	PCT	C07C 323/60		
36.		WO 98/37877	9/3/98	PCT	A61K 31/16		
37.		WO 97/24117	7/10/97	PCT	A61K 31/19		
38.		WO 97/20824	6/12/97	PCT	C07D 241/04		
39.		WO 96/11209	4/18/96	PCT	C07K 5/06		
40.		WO 96/06074	2/29/96	PCT	C07C 259/06		
41.		WO 95/29892	11/9/95	PCT	C07D 207/327		
42.		WO 95/13289	5/18/95	PCT	C07K 5/062		
43.		WO 95/09841	4/13/95	PCT	C07C 323/60		
44.		WO 94/24140	10/27/94	PCT	C07H 13/04		
45.		WO 94/02466	2/3/94	PCT	C07D 221/14		
46.	cl	WO 93/20047	10/14/93	PCT	C07C 317/44		

Examiner:


clx

Date Considered:

5/4/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 311408213 US



RECEIVED  
SEP 29 2003  
SEARCHED INDEXED  
SERIAL NO. 10/603,441

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 2 of 3

ATTORNEY DOCKET NO.	SERIAL NO.
01136/1/US	10/603,441
APPLICANT	Daniel P. Becker, et al.
FILING DATE	GROUP
June 25, 2003	1614 1625

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
47.	cc	WO 90/05719	5/31/90	PCT	C07C 323/62	—	—

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
48.	cc	Brown, "Synthetic Inhibitors of Matrix Metalloproteinases"; <i>Matrix Metalloproteinases</i> , pp. 243-261 (Academic Press, San Diego, CA, Eds. Park, W.C., & Mecham, R.P., 1998)
49.		Dack, et al., "Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors," CA 131:44740 (1999)
50.		Denis, et al., "Matrix metalloproteinase inhibitors: Present achievements and future prospects," <i>Invest. New Drugs</i> , 15:175-185 (1997)
51.		Freije, et al., "Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas," <i>J. Biol. Chem.</i> , 269(24), pp. 16766-16773 (1994)
52.		Gearing, et al., "Processing of tumour necrosis factor- $\alpha$ precursor by metalloproteinases", <i>Nature</i> , 370:555-557 (1994)
53.		Gu, et al., "S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death," <i>Science</i> , 297, 1186-1190 (2002)
54.		Hughes, et al., "Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism <i>in situ</i> and <i>in vitro</i> ," <i>Biochem. J.</i> , 305, 799-804 (1995)
55.		Kenyon, et al., "A Model of Angiogenesis in the Mouse Cornea," <i>Investigative Ophthalmology &amp; Visual Science</i> , Vol. 37, No. 8:1625-32 (July 1996)
56.		Knight, et al., "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases," <i>FEBS Lett.</i> , 296(3):263-266 (1992)
57.		Kuzmic, et al., "High-throughput screening of enzyme inhibitor: simultaneous determination of tight-binding inhibition constants and enzyme concentration," <i>Anal. Biochem.</i> , 286, 45-50 (2000)
58.	cc	Luckow, et al., "Insect Cell Expression Technology", <i>Protein Engineering: Principles and Practice</i> , pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996)


Examiner:

Ch

Date Considered:

5/4/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED  
SEP 29 2003  
RECEIVED  
SEPTEMBER 16 2003

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTORNEY DOCKET NO.	SERIAL NO.
		01136/J/US	10/60341
		APPLICANT	
		Daniel P. Becker, et al.	
		FILING DATE	GROUP
Sheet 3 of 3		June 25, 2003	1614 / 625

#### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
59.	<i>cl</i>	Luckow, et al., "Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherichia coli," <i>J. Virol.</i> , 67(8):4566-4579 (1993)
60.		McClure, et al., "Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases," <i>CA</i> 131:125454 (1999) [CA Plus Accession No. 1999:468334]
61.		McGeehan, et al., "Regulation of tumour necrosis factor- $\alpha$ processing by a metalloproteinase inhibitor," <i>Nature</i> , 370:558-561 (1994)
62.		Mitchell, et al., "Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage," <i>J. Clin. Invest.</i> , 97(3):761-768 (1996)
63.		Rasmussen, et al., "Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat," <i>Pharmacol. Ther.</i> , 75(1):69-75 (1997)
64.		Reboul, et al., "The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes," <i>J. Clin. Invest.</i> , 97(9):2011-2019 (1996).
65.		Schwartz, et al., "Synthetic inhibitors of bacterial and mammalian interstitial collagenases," <i>Prog. in Med. Chem.</i> , 29:271-334 (1992).
66.		Tang, "ADAMTS: a novel family of extracellular matrix proteases," <i>Int'l J. Biochem. Cell Biol.</i> , 33, 33-44 (2001)
67.	<i>cl</i>	Woessner, "The Matrix Metalloproteinase Family," <i>Matrix Metalloproteinases</i> , pp. 1-14 (Academic Press, San Diego, CA, Eds. Parks, W.C. & Mecham, R.P., 1998)

Examiner:

*cl*

Date Considered:

5/4/05

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.